Mexiletine (Namuscla®) accepted for use within NHS Scotland for symptomatic treatment of myotonia in adult patients with non-dystrophic myotonic disorders

Approval of this resubmitted application is based on a short-term, phase III, crossover study; results of which showed that mexiletine significantly improved muscle stiffness compared with placebo when measured on a visual analogue scale.

Source:

Scottish Medicines Consortium